Description:CB-839, with the CAS number 1439399-58-2, is a small molecule inhibitor that specifically targets the enzyme glutaminase. This compound is of particular interest in cancer research due to its potential to disrupt the metabolic pathways that cancer cells rely on for growth and proliferation. By inhibiting glutaminase, CB-839 aims to reduce the availability of glutamine, an amino acid that many tumors utilize to support their energy needs and biosynthetic processes. The substance has been studied in various preclinical and clinical settings, particularly in relation to solid tumors and hematological malignancies. CB-839 is typically characterized by its moderate solubility in organic solvents and its stability under physiological conditions. Its mechanism of action highlights the importance of metabolic reprogramming in cancer therapy, making it a promising candidate for combination therapies aimed at enhancing the efficacy of existing treatments. As research continues, the full therapeutic potential and safety profile of CB-839 are being evaluated in clinical trials.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![2-Pyridineacetamide, N-[5-[4-[6-[[2-[3-(trifluoromethoxy)phenyl]acetyl]amino]-3-pyridazinyl]butyl]…](https://static.cymitquimica.com/products/IN/thumb/DA001IMQ.jpg)
